SCHEMBL6429547

SCHEMBL6429547

COc1ccc(CN2C(=O)C(Cl)=C(c3ccc(Cl)cc3)C2=O)cc1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CMA1 P23946 1/20 0.54
NR1H2 P55055 2/20 0.52
NR1H3 Q13133 2/20 0.52
GSK3A P49840 1/20 0.51
GSK3B P49841 1/20 0.51
CASP3 P42574 1/20 0.50
RAD51 Q06609 1/20 0.49
KDM4E B2RXH2 1/20 0.49
SCN9A Q15858 1/20 0.48
NPBWR1 P48145 1/20 0.48
CHRM5 P08912 1/20 0.46
EDNRA P25101 1/20 0.46
MEN1 O00255 2/20 0.44
ALDH1A1 P00352 2/20 0.44
KMT2A Q03164 2/20 0.44
BLM P54132 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6428843 0.88 NR1H2 (0.52) NR1H2NR1H3SCN9AMEN1ALDH1A1
SCHEMBL6426743 0.86 CMA1 (0.57) CMA1NR1H2NR1H3KDM4ESCN9A
SCHEMBL6427394 0.84 NR1H2 (0.51) NR1H2NR1H3NPBWR1CHRM5
SCHEMBL8331785 0.83 CMA1 (0.70) CMA1GSK3AGSK3BCASP3KDM4E
SCHEMBL6426845 0.81 MAPT (0.50) NR1H2NR1H3CASP3ALDH1A1KMT2A
SCHEMBL6427000 0.81 NR1H2 (0.60) NR1H2NR1H3RAD51KDM4ESCN9A
SCHEMBL30320663 0.80 NR1H2 (0.71) CMA1NR1H2NR1H3GSK3AGSK3B
SCHEMBL6428883 0.80 NR1H2 (0.48) NR1H2NR1H3RAD51KDM4EMEN1
SCHEMBL6426484 0.79 APAF1 (0.52) NR1H2NR1H3RAD51MEN1ALDH1A1
SCHEMBL6427927 0.76 MAPT (0.52) NR1H2NR1H3KDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005024755-A2 MEDICAMENTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS OR DIABETES DECIPHERA PHARMACEUTICALS, LLC. (US) 2005-03-17 WO disclosed